Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms

Abstract Background Pioglitazone (PIO), a thiazolidinediones drug, is a well-known anti-diabetic medicine, but its anti-atherosclerotic effects remain controversial. Thus it is important to investigate the effects of PIO on atherogenesis and the relevant mechanisms. Methods For in vitro studies, pri...

Full description

Bibliographic Details
Main Authors: Yuling Tian, Tao Chen, Yan Wu, Lin Yang, Lijun Wang, Xiaojuan Fan, Wei Zhang, Jiahao Feng, Hang Yu, Yanjie Yang, Juan Zhou, Zuyi Yuan, Yue Wu
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Cardiovascular Diabetology
Subjects:
Pioglitazone
AMPK
T cell
Signaling
Atherosclerosis
Online Access:http://link.springer.com/article/10.1186/s12933-017-0623-6

Internet

http://link.springer.com/article/10.1186/s12933-017-0623-6

Similar Items